Discovery of 4,6-bis(2-((E)-benzylidene)hydrazinyl)pyrimidin-2-Amine with antibiotic activity
Files
(Published Version)
Date
2019
Authors
Russell, C.C.
Stevens, A.
Young, K.A.
Baker, J.R.
McCluskey, S.N.
Khazandi, M.
Pi, H.
Ogunniyi, A.
Page, S.W.
Trott, D.J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
ChemistryOpen, 2019; 8(7):896-907
Statement of Responsibility
Cecilia C. Russe, Andrew Stevens, Kelly A. Young, Jennifer R. Baker ... Manouchehr Khazandi ... Abiodun Ogunniyi ... et al.
Conference Name
Abstract
Robenidine (E)-N'-((E)-1-(4-chlorophenyl)ethylidene)-2-(1-(4-chlorophenyl)ethylidene)hydrazine-1-carboximidhydrazide displays methicillin-resistant Staphyoccoccus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) MICs of 2 μg mL-1. Herein we describe the structure-activity relationship development of a novel series of guanidine to 2-aminopyrimidine isosteres that ameliorate the low levels of mammalian cytotoxicity in the lead compound while retaining good antibiotic activity. Removal of the 2-NH2 pyrimidine moiety renders these analogues inactive. Introduction of a central 2-NH2 triazine moiety saw a 10-fold activity reduction. Phenyl to cyclohexyl isosteres were inactive. The 4-BrPh and 4-CH3Ph with MIC values of 2 and 4 μg mL-1, against MRSA and VRE respectively, are promising candidates for future development.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
©201x The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.